We then examined c-Met expression levels in sensitive and resistant cell lines and found an upregulation of c-Met expression in the HCC827OR and H1975OR cells (Fig. 1C), suggesting that overexpression of c-Met may be an essential driver of osimertinib resistance in NSCLC. This evidence concerns the gene MET and non-small cell lung carcinoma.